Anaxomics' TPMS technology offers virtual experimentation for in silico clinical trials, making them faster, more economic and yielding more insightful results.
Anaxomics brings the power of systems biology to clinical trials.
In silico Clinical Trials (ISCT) are computer simulations of clinical trials. They are valuable for:
- Optimizing clinical trial design
- Studying drug effects in underrepresented subpopulations in clinical trials
- Identifying biomarkers to monitor in clinical trials
- Reducing the time, costs, and risks of trials.
What does Anaxomics offer?
Anaxomics' ISCT methodology relies on a quantitative systems pharmacology (QSP) approach, which combines physiologically-based pharmacokinetic (PBPK) modeling with systems biology and AI-based modeling Therapeutic Performance Mapping System (TPMS). This enables the capture of drug response in virtual patient populations with individual and tissue-specific predictions, allowing for realistic simulations of human population behavior in silico.
Anaxomics' proprietary TPMS technology integrates biological, pharmaceutical and medical data into systems biology models to realistically simulate in silico the behavior of human populations. While classical system biology approaches rely on the statistical assessment of clinical variables, TPMS evaluates the therapeutic response in a more global manner, analyzing clinical trial in the context of human physiology, tracking the deep metabolic implications. This holistic approach holds the potential to generate mechanistic hypothesis for clinical observations.
ISCT protocol overview.
The protocol is divided into three main stages:
- Phase I, including trial design and information compilation
- Phase II, comprising mathematical modelling
- Phase III, consisting of data analysis according to the trial design.
- Gutiérrez-Casares, JR., J. Quintero, G. Jorba, V. Junet, V. Martínez, T. Pozo-Rubio, B. Oliva, X.
Daura, JM. Mas and C. Montoto (2021). Methods to Develop an in silico Clinical Trial: Computational
Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate. Frontiers in Psychiatry. 12(1902).
- Gutiérrez-Casares, JR., J. Quintero, C. Segú-Vergés, P. Rodríguez, T. Pozo-Rubio, M. Coma and C.
Montoto (2023). In silico clinical trial evaluating lisdexamfetamine's and methylphenidate's
mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual
patients' population. Frontiers in Psychiatry. 14:939650.